Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982275 | 1.00 | HIF1A (0.71) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL9346424 | 0.90 | HIF1A (0.69) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL9346409 | 0.90 | HIF1A (0.69) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL9396879 | 0.85 | HIF1A (0.72) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL23982423 | 0.85 | HIF1A (0.75) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL98134 | 0.85 | HIF1A (0.75) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL2048956 | 0.85 | HIF1A (0.75) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL17612282 | 0.85 | HIF1A (0.75) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL2408903 | 0.85 | HIF1A (0.75) | HIF1ATP53SMN1; SMN2PNPLMNA | |
| SCHEMBL5982127 | 0.84 | HIF1A (0.59) | HIF1ATP53SMN1; SMN2PNPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | HIF1A 2249/4885TP53 3393/4885SMN1; SMN2 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.